UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported): March 9, 2021
Emerald Health Pharmaceuticals Inc.
(Exact name of issuer as specified in its charter)
Delaware
State or other jurisdiction of incorporation or organization
82-0669961
(I.R.S. Employer Identification No.)
5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121
(Full mailing address of principal executive offices)
(858) 352 - 0622
(Issuer’s telephone number, including area code)
Title of each class of securities issued pursuant to Regulation A: Common Stock
Item 9. Other Events
Press Release
On March 9, 2021, Emerald Health Pharmaceuticals (the “Company”) announced the final closing date for its Regulation A, Tier 2 offering. The offering will close on March 28, 2021 or once the maximum offering amount of $67.1 million is reached, whichever comes first.
A copy of the press release announcing the closing of the offering is attached as Exhibit 16.1(b) hereto.
The information contained herein, including Exhibit 16.1(b), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the information be deemed incorporated by reference into any of our Securities and Exchange Commission filings, except as shall be expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 1-U and Exhibit 16.1(b) will not be deemed an admission as to the materiality of any information in this Item 9.
Exhibits
SIGNATURES
Pursuant to the requirements of Regulation A, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | EMERALD HEALTH PHARMACEUTICALS INC., |
| | a Delaware corporation |
| | |
| | By: | /s/ James DeMesa |
| | | James DeMesa |
| | | President and Chief Executive Officer |
Date: March 9, 2021
2
